3 completed, 2 not yet recruiting, 2 terminated. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Not yet recruiting 2, Terminated 2 |
Follow Chronic Stroke: new trials by email Literature Review of Chronic Stroke trials Research Report on Chronic Stroke
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rimonabant for Improving Walking Ability in Patients With Chronic Stroke Rimonabant, Placebo - Chronic Stroke | Phase 2 | Not yet recruiting | Sinfatin S.L | 80 | 2026-11-30 | 2026-11-03 |
| ANIMATOR - RehUP BCI Controlled Robotic Therapy vs. an Attention-based Control RehUp BCI Intervention, Control Therapy - Chronic Stroke | Phase 2 | Not yet recruiting | University of Calgary | 60 | 2024-08-01 | 2024-08-09 |
| IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE Cerebrolysin, non-invasive brain stimulation, Placebo - Chronic Stroke, Subacute Stroke | Phase 2 | Terminated | Ever Neuro Pharma GmbH | 4 | 2021-06-25 | 2022-07-28 |
| An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 in Patients with Chronic Stroke GXNPC1 - Chronic Stroke | Phase 2 | Completed | Gwo Xi Stem Cell Applied Technology Co., Ltd. | 12 | 2020-02-06 | 2024-09-19 |
| Effects of EMG-driven Robot-assisted Therapy for the Distal Upper Limb Motor Function in the Chronic Stroke Patients With Botox Injections Hand of Hope, Botulinum toxin type A injection - Chronic Stroke, Spasticity as Sequela of Stroke | Phase 2 | Completed | Cheng-Hsin General Hospital | 24 | 2020-01-09 | 2024-03-19 |
| Investigation of Neural Stem Cells in Ischemic Stroke CTX0E03 Drug Product and delivery device, Placebo - Ischemic Stroke, Chronic Stroke | Phase 2 | Terminated | ReNeuron Limited | 15 | 2018-08-31 | 2021-08-13 |
| Influence of G-CSF and EPO on Associative Learning and Motor Skills granulocyte - colony stimulating factor (G-CSF), erythropoetin (EPO) - Chronic Stroke, Amyotrophic Lateral Sclerosis | Phase 2 | Completed | University Hospital Muenster | 180 | 2006-03-01 | 2009-04-23 |
Amyotrophic Lateral Sclerosis (1) · Brain Diseases (1) · Cerebral Infarction (1) · Cerebrovascular Disorders (1) · Ischemic Stroke (1) · Paresis (1)
Central Nervous System Diseases (2) · Nervous System Diseases (2) · Brain Infarction (1) · Brain Ischemia (1) · Cardiovascular Diseases (1) · Infarction (1) · Ischemia (1) · Metabolic Diseases (1) · Motor Neuron Disease (1) · Necrosis (1) · Neurodegenerative Diseases (1) · Neurologic Manifestations (1) · Neuromuscular Diseases (1) · Nutritional and Metabolic Diseases (1) · Pathologic Processes (1)
Botulinum Toxins, Type A (1) · Erythropoietin (1) · Granulocyte Colony-Stimulating Factor (1) · Rimonabant (1) · cerebrolysin (1)
Cheng-Hsin General Hospital (1) · Ever Neuro Pharma GmbH (1) · Gwo Xi Stem Cell Applied Technology Co., Ltd. (1) · ReNeuron Limited (1) · Sinfatin S.L (1) · University Hospital Muenster (1) · University of Calgary (1)
Taiwan (2) · Austria (1) · Canada (1) · Germany (1) · Spain (1) · United States (1)
Andreas Winkler, MD, MSc (1) · Chiu Ts Lang, Director (1) · Richard Beckman, MD (1) · Sean P Dukelow, MD PhD FRCPC (1)
PMID 21423758, PMID 21625426, PMID 35130557, PMID 38419030, PMID 41541089
2025 (1)